Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
26 January 2017Website:
http://www.anaptysbio.comNext earnings report:
11 March 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Thu, 21 Nov 2024 00:00:12 GMTDividend
Analysts recommendations
Institutional Ownership
ANAB Latest News
AnaptysBio (ANAB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the third quarter ended Sept. 30, 2024 and provided a business update.
SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its senior management team, are scheduled to participate in multiple upcoming investor conferences:
The biotech saw some action thanks in no small part to a new analyst note. This reiterated an existing buy recommendation at a relatively high target price.
AnaptysBio, Inc. 14-week results from the phase 2b study, using ANB032 for the treatment of patients with moderate-to-severe Atopic Dermatitis, expected in December 2024. The global Atopic dermatitis market is expected to reach $19.49 billion by 2034. Top-line 12-week data from the phase 2b study, using rosnilimab for the treatment of patients with moderate-to-severe rheumatoid arthritis, expected in Q1 of 2025.
AnaptysBio, Inc. (ANAB) came out with a quarterly loss of $1.71 per share versus the Zacks Consensus Estimate of a loss of $1.20. This compares to loss of $1.50 per share a year ago.
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update.
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
HC Wainwright analyst initiated coverage on AnaptysBio Inc ANAB, a clinical-stage biotechnology company focused on delivering immunology therapeutics.
AnaptysBio (ANAB) experienced a surge in stock price during the last trading session with higher than usual trading volume. Recent changes in earnings estimates indicate that the stock may continue to show strength in the future.
- 1(current)
What type of business is AnaptysBio?
AnaptysBio, Inc. is a company that specializes in the development of immunological therapeutic drugs. AnaptysBio has a lineup of programs including Etokimab, ANB019, ANB030, and ANB032, which are designed to modulate therapeutic targets genetically linked to inflammatory diseases in humans. Previously known as Anaptys Biosciences, Inc., the company changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was founded in 2005 and is headquartered in San Diego, California.
What sector is AnaptysBio in?
AnaptysBio is in the Healthcare sector
What industry is AnaptysBio in?
AnaptysBio is in the Biotechnology industry
What country is AnaptysBio from?
AnaptysBio is headquartered in United States
When did AnaptysBio go public?
AnaptysBio initial public offering (IPO) was on 26 January 2017
What is AnaptysBio website?
https://www.anaptysbio.com
Is AnaptysBio in the S&P 500?
No, AnaptysBio is not included in the S&P 500 index
Is AnaptysBio in the NASDAQ 100?
No, AnaptysBio is not included in the NASDAQ 100 index
Is AnaptysBio in the Dow Jones?
No, AnaptysBio is not included in the Dow Jones index
When was AnaptysBio the previous earnings report?
No data
When does AnaptysBio earnings report?
The next expected earnings date for AnaptysBio is 11 March 2025